Browsing Histopathology & Morbid Anatomy (Scholarly Publications) by Title
Now showing items 17-36 of 61
-
Detection of a Tyrosine Phosphatase LAR on Intestinal Epithelial Cells and Intraepithelial Lymphocytes in the Human Duodenum.
(Hindawi, 2005)Studies of tyrosine phosphorylation in the human duodenum have indicated that proliferating cells in the middle portion of the duodenal crypt were devoid of this feature, suggesting that tyrosine kinase activation is not ... -
Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention.
(2014)Despite decades of research, ovarian cancer is still associated with unacceptably high mortality rates, which must be addressed by novel therapeutic approaches. One avenue through which this may be achieved is targeting ... -
THE EMT-ACTIVATOR ZEB1 IS UNRELATED TO PLATINUM DRUG RESISTANCE IN OVARIAN CANCER BUT PREDICTIVE OF SURVIVAL
(2014)Background: Ovarian cancer is treated by surgery followed by platinum/taxane combination chemotherapy. Initial response rates are high, but up to 80% of ovarian cancer patients will eventually relapse with drug-resistant ... -
Endosomal gene expression: a new indicator for prostate cancer patient prognosis?
(2015)Prostate cancer continues to be a major cause of morbidity and mortality in men, but a method for accurate prognosis in these patients is yet to be developed. The recent discovery of altered endosomal biogenesis in prostate ... -
Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer.
(2009)The identification of biomarkers that distinguish between aggressive and indolent forms of prostate cancer (PCa) is crucial for diagnosis and treatment. In this study, we used cultured cells derived from prostate tissue ... -
Epitope presentation is an important determinant of the utility of antigens identified from protein arrays in the development of autoantibody diagnostic assays
(Elsevier, 2012)Autoantibodies represent an attractive biomarker for diagnostic assays principally due to the stability of immunoglobulin in patient serum facilitating measurement with conventional assays. Immune responses to tumorigenesis ... -
Epstein-Barr virus-positive mucocutaneous ulcer: A unique case occurring in association with cholelithiasis in a gallbladder
(2020)Epstein-Barr virus (EBV)-positive mucocutaneous ulcer is a lymphoproliferative disorder occurring in patients due to iatrogenic or age-related immunosuppression confined to the oropharynx, skin, and gastrointestinal tract. ... -
ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.
(Springer Verlag, 2009)Background: The H69CIS200 and H69OX400 cell lines are novel models of low- level platinum-drug resistance. Resistance was not associated with increased cellular glutathione or decreased accumulation of platinum, rather ... -
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
(2011)Background: Platinum-based chemotherapy is the standard of care for ovarian cancer and non-small cell lung cancer (NSCLC). However, resistance to platinum agents invariably develops. Targeted therapies, such as tyrosine ... -
Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival.
(2010)BACKGROUND: Overexpression of the fatty acid synthase (FASN) gene has been implicated in prostate carcinogenesis. We sought to directly assess the oncogenic potential of FASN. METHODS: We used immortalized human prostate ... -
FOXA1 is a potential oncogene in anaplastic thyroid carcinoma
(2009)Purpose: FOXA1 is a mammalian endodermal transcription factor belonging to the human forkhead box gene family that plays a role in certain tumor types. Here, we investigated the potential role of FOXA1 in human thyroid ... -
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?
(2009)PURPOSE Gleason grading is an important predictor of prostate cancer (PCa) outcomes. Studies using surrogate PCa end points suggest outcomes for Gleason score (GS) 7 cancers vary according to the predominance of pattern ... -
Hands-free sample preparation platform for nucleic acid analysis.
(2009)A Lab-On-Chip system with an instrument is presented which is capable of performing total sample preparation and automated extraction of nucleic acid from human cell samples fixed in a methanol based solution. The target ... -
The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers.
(2009)We investigated the role of the C1772T polymorphisms in exon 12 of the Hypoxia-inducible factor-1 alpha (HIF-1alpha) gene C1772T genotype in prostate cancer (PCa) and amplification of the hypoxic response. We identified ... -
Human papillomavirus detection and genotyping, by HC2, Full-Spectrum HPV and Molecular Beacon Real-Time HPV assay in an Irish colposcopy clinic
(2014)Cervical screening programmes are moving towards HPV testing as part of the screening process and as a triage for colposcopy. Three HPV detection methods were evaluated using cervical cytology specimens from colposcopy ... -
Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer
(2015)Background: Ovarian cancer is associated with poor long-term survival due to late diagnosis and development of chemoresistance. Tumour hypoxia is associated with many features of tumour aggressiveness including increased ... -
"If you can't treat HPV, why test for it?" Women's attitudes to the changing face of cervical cancer prevention: A focus group study
(2014)Open Access Research article “If you can’t treat HPV, why test for it?” Women’s attitudes to the changing face of cervical cancer prevention: a focus group study Judith McRae1*, Cara Martin2, John O’Leary3, Linda Sharp1 ... -
In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.
(2014)The development of a drug-resistant cell line can take from 3 to 18 months. However, little is published on the methodology of this development process. This article will discuss key decisions to be made prior to starting ...